Program
QCZ484
A development code.
In Novartis's pipeline, AGT siRNA
. Its studies are mostly in Hypertension · Hypercholesterolemia, led by Novartis.
Furthest: phase 2, since Mar 3, 20254 company-led studies, 3 open or runningNext primary completion: Apr 28, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 43 open or running | phase 2since Mar 3, 2025 | Mar 3, 2025 | Apr 28, 2027phase 2 · NCT07610278 |
- Named in Novartis’s own pipeline as
QCZ484
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 3, 2025First study: phase 2 study in HypertensionFirst studyNCT06857955 · 396 enrolled · United States, Japan, Singapore
- Mar 25, 2025Phase 1 study in HypertensionNCT06905327 · 56 enrolled · Australia, New Zealand
- Apr 15, 2026Phase 2 study in HypertensionNCT07543120 · 323 planned · United States, Japan, Singapore
- May 20, 2026Phase 2 study in HypercholesterolemiaNCT07610278 · 120 planned · United States
Ahead
- Apr 28, 2027Primary completion: phase 2 study in HypercholesterolemiaNCT07610278
- May 7, 2031Primary completion: phase 2 study in HypertensionNCT07543120
TargetBeta
“AGT siRNA”the company's pipeline, read by Claude · source
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07610278Hypercholesterolemia · United States | 2 | Recruiting | Apr 28, 2027 | 120 |
| NCT07543120Hypertension · United States, Japan, Singapore | 2 | Recruiting | May 7, 2031 | 323 |
| NCT06905327Hypertension · Australia, New Zealand | 1 | Completed | Sep 25, 2024 | 56 |
| NCT06857955Hypertension · United States, Japan, Singapore | 2 | Active, not recruiting | Sep 17, 2026 | 396 |
How it is read
Names in the registry
- “QCZ484”, 4 entries
Codes read as this program: QCZ484.
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.